Literature DB >> 17198092

Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.

Franz O Smith, Stephanie L Goff, Jacob A Klapper, Catherine Levy, Tamika Allen, Sharon A Mavroukakis, Steven A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17198092      PMCID： PMC2151199          DOI： 10.1097/01.cji.0000211334.06762.89

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  2 in total

1.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 2.  Gastrointestinal perforations associated with interleukin-2 administration.

Authors:  David M Heimann; Douglas J Schwartzentruber
Journal:  J Immunother       Date:  2004 May-Jun       Impact factor: 4.456
  2 in total
  13 in total

Review 1.  Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.

Authors:  Taher Abu-Hejleh; James J Mezhir; Michael J Goodheart; Thorvardur R Halfdanarson
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  Spontaneous free perforation of the small intestine in adults.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

Review 4.  Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Authors:  Jennifer A Wargo; Alexandre Reuben; Zachary A Cooper; Kevin S Oh; Ryan J Sullivan
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 5.  Ipilimumab and its toxicities: a multidisciplinary approach.

Authors:  Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal:  Oncologist       Date:  2013-06-17

6.  Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.

Authors:  Bianca Heemskerk; Ke Liu; Mark E Dudley; Laura A Johnson; Andrew Kaiser; Stephanie Downey; Zhili Zheng; Thomas E Shelton; Kant Matsuda; Paul F Robbins; Richard A Morgan; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

Review 7.  Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.

Authors:  Tasha Hughes; Matthew Klairmont; William H Sharfman; Howard L Kaufman
Journal:  Cancer Biol Ther       Date:  2021-11-19       Impact factor: 4.742

Review 8.  Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.

Authors:  Ahmad Tarhini
Journal:  Scientifica (Cairo)       Date:  2013-04-17

9.  Melanoma Metastasizing to the Small Intestine: A Case Report Illustrating Symptomatic and Asymptomatic Involvement.

Authors:  Fnu Asad-Ur-Rahman; Aamer Abbass; Umair Majeed; Udayakumar Navaneethan
Journal:  Cureus       Date:  2016-05-13

10.  Immuno-oncology combinations: raising the tail of the survival curve.

Authors:  Samuel J Harris; Jessica Brown; Juanita Lopez; Timothy A Yap
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.